Japan dietary supplements linked to 157 hospitalisations

Japanese dietary supplements at the centre of an expanding health scare have now been linked to at least 157 hospitalisations, a health ministry official said.

The figure reflects an increase from the 114 hospitalisation cases that Kobayashi Pharmaceutical said on Friday were linked to its products containing red yeast rice, or "beni koji".

A Kobayashi spokeswoman confirmed the latest hospitalisation cases without elaborating further.

On Friday, Kobayashi said it was investigating five deaths potentially linked to the dietary supplements, which are meant to lower cholesterol.

The government and the company are probing whether the supplements caused the deaths and other health problems, mostly with kidneys.

'Beni konji' safety probe

Kobayashi Pharmaceutical is a household name in Japan, offering a wide range of health-related products.

It announced on March 22 that it was recalling three kinds of over-the-counter tablets containing "beni koji" after customers reported kidney problems.

Red yeast rice consists of rice fermented with a mould culture. It has been used in food, alcoholic drinks and folk medicines for centuries around East Asia.

Kobayashi has said that it detected a potentially toxic acid produced by the mould at one of its factories.

Government officials have been carrying out inspections at the firm's facilities in recent days.

Wider market fallout

The company has said it also sold red yeast rice to around 50 other firms in Japan and two in Taiwan.

Some of those companies have preventively recalled food products containing the ingredient, including a rose-coloured sake and a salad dressing.

Taiwanese companies have preventively recalled 154 products containing red yeast rice in the wake of the scare, the island's health authorities said.

A woman in her 70s in Taiwan had also reportedly developed kidney failure after taking Kobayashi's supplements for several years.